We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
Read MoreHide Full Article
Emergent BioSolutionsInc. (EBS - Free Report) reported an adjusted loss of $1.27 per share in third-quarter 2022, significantly wider than the Zacks Consensus Estimate of a loss of 6 cents. In the year-ago quarter, EBS reported a loss of 36 cents per share.
Revenues in the reported quarter were $240 million, down 27% from the prior-year period’s level. The revenue decline was caused by a reduction in COVID-related contract development and manufacturing (CDMO) revenues. Revenues missed the Zacks Consensus Estimate of $268 million.
Shares of Emergent BioSolutions have declined 21.2% in the year compared with the industry’s 20.9% fall.
Image Source: Zacks Investment Research
Quarter in Detail
Total product sales decreased 31.2% from the year-ago quarter’s level to $186.2 million, owing to the year-over-year decreased sales of Narcan nasal spray, ACAM2000 and other products. The decline was slightly offset by a solid year-over-year increase in anthrax vaccine sales.
Sales of anthrax vaccines (BioThrax and AV7909) were $24.2 million in the reported quarter, up 55.1% year over year. The increase in sales of anthrax vaccines can be attributed to the timely deliveries of the Anthrax vaccines to the U.S Government (USG), specifically the Strategic National Stockpile (SNS).
Emergent received an AV7909 contract modification in September 2021 valued at approximately $399 million to deliver additional AV7909 doses to the USG through March 2023.
Narcan (naloxone HCl) nasal spray added $87.9 million to product sales, down 34.1% year over year. The decline in sales can be attributed to erosion in sales following the launch of a generic in December 2021. The downside was slightly offset by higher volumes of Narcan sprays sold to public interest customers in the United States and Canada and from the sales of the aforementioned authorized generic product licensed to Sandoz, the generic arm of Novartis (NVS - Free Report) .
Emergent authorized Novartis’ generic arm, Sandoz, to distribute a generic Narcan nasal spray, launched in the United States in December 2021.
Emergent reported $49 million in revenues for its smallpox vaccine ACAM2000 in the third quarter, down 39.3% year over year. The decline was due to fewer doses sold to the U.S. Government. The downfall was partially offset by a rise in the number of doses sold to the non-U. S customers at a higher price per dose.
Other product sales were $25.1 million, down 38.6% year over year.
Revenues from contracts and grants increased 3% year over year to $17.4 million.
Total CDMO revenues reached 36.4 million, compared to the year-ago quarter’s revenues of $41.6 million. While CDMO services revenues declined 67.9% year over year to $36.2 million, the CDMO lease revenues increased $71.2 million from the year-ago quarter, reaching $0.2 million.
The decline in CDMO services revenues was due to lower combined revenues of $82 million from AstraZeneca (AZN - Free Report) and Janssen, a Johnson &Johnson (JNJ - Free Report) subsidiary, which resulted in lower production-related work carried out at one of Emergent’s facilities, which reduced manufacturing activities. Emergent reversed $8.3 million of previously recognized revenues under the Janssen contract.
In July 2020, J&J and Emergent entered into an agreement to provide contract development and manufacturing (CDMO) services for J&J’s single-shot, adenovirus-based COVID-19 vaccine for five years. In June 2022, the companies announced their decision to terminate the deal, citing contract breaches.
The increase in CDMO lease revenues was driven by the reversal of revenues of $86 million in the third quarter of 2021 related to Emergent’s public-private COVID-19 development partnership with BARDA in November 2021. The increase was partially offset by a $15.1-million decline in lease revenues related to the contract with Janssen, a subsidiary of Johnson & Johnson.
We note that Emergent had received a setback last year when there was a manufacturing mishap at its Bayview facility where COVID-19 vaccine ingredients of J&J and AstraZeneca reportedly got mixed and led to several faulty batches of J&J’s vaccine. Emergent lost its contract for AstraZeneca’s vaccine following the mishap.
Emergent reported an adjusted EBITDA loss of $15.2 million for the third quarter, wider than the year-ago quarter’s loss of $3.3 million.
Emergent Biosolutions Inc. Price, Consensus and EPS Surprise
Emergent has issued fresh guidance for total revenues, adjusted EBITDA and CDMO services while providing updated ranges for its other business segments.
The company lowered its previous guidance for full-year 2022 revenues from the range of $1.15-$1.25 billion and now expects it to be between $1.05 billion and $1.10 billion.
Management revised anthrax sales guidance and currently expects sales of $260-$275 million from anthrax vaccines, down from the previous guidance of $280-$300. The company has raised the revenue guidance for Narcan nasal spray and smallpox vaccine. It now expects revenues from smallpox vaccine to be in the range of $63-$63 million compared with the previously guided range of $225-$250 million. Revenues from the Narcan nasal spray are expected to be between $350-$365 million, up from $300-$340 million expected previously. The projection for revenues from other products and Contracts and Grants was updated in the range of $167-$172 million from its previously expected range of $235-$240 million.
Emergent expects CDMO revenues to be in the range of $100-$110 million, revised from $1052 - $110 million.
The company now expects adjusted EBITDA in the range of $0-$30 million, down from $80-$120 million expected previously.
Emergent also anticipates lower adjusted net income(loss) within $(100)-$(70) million, compared to the previous expectation of $(15)-$10 million.
Zacks Rank
Currently, Emergent BioSolutions has a Zacks Rank #3 (Hold).
Image: Bigstock
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
Emergent BioSolutions Inc. (EBS - Free Report) reported an adjusted loss of $1.27 per share in third-quarter 2022, significantly wider than the Zacks Consensus Estimate of a loss of 6 cents. In the year-ago quarter, EBS reported a loss of 36 cents per share.
Revenues in the reported quarter were $240 million, down 27% from the prior-year period’s level. The revenue decline was caused by a reduction in COVID-related contract development and manufacturing (CDMO) revenues. Revenues missed the Zacks Consensus Estimate of $268 million.
Shares of Emergent BioSolutions have declined 21.2% in the year compared with the industry’s 20.9% fall.
Image Source: Zacks Investment Research
Quarter in Detail
Total product sales decreased 31.2% from the year-ago quarter’s level to $186.2 million, owing to the year-over-year decreased sales of Narcan nasal spray, ACAM2000 and other products. The decline was slightly offset by a solid year-over-year increase in anthrax vaccine sales.
Sales of anthrax vaccines (BioThrax and AV7909) were $24.2 million in the reported quarter, up 55.1% year over year. The increase in sales of anthrax vaccines can be attributed to the timely deliveries of the Anthrax vaccines to the U.S Government (USG), specifically the Strategic National Stockpile (SNS).
Emergent received an AV7909 contract modification in September 2021 valued at approximately $399 million to deliver additional AV7909 doses to the USG through March 2023.
Narcan (naloxone HCl) nasal spray added $87.9 million to product sales, down 34.1% year over year. The decline in sales can be attributed to erosion in sales following the launch of a generic in December 2021. The downside was slightly offset by higher volumes of Narcan sprays sold to public interest customers in the United States and Canada and from the sales of the aforementioned authorized generic product licensed to Sandoz, the generic arm of Novartis (NVS - Free Report) .
Emergent authorized Novartis’ generic arm, Sandoz, to distribute a generic Narcan nasal spray, launched in the United States in December 2021.
Emergent reported $49 million in revenues for its smallpox vaccine ACAM2000 in the third quarter, down 39.3% year over year. The decline was due to fewer doses sold to the U.S. Government. The downfall was partially offset by a rise in the number of doses sold to the non-U. S customers at a higher price per dose.
Other product sales were $25.1 million, down 38.6% year over year.
Revenues from contracts and grants increased 3% year over year to $17.4 million.
Total CDMO revenues reached 36.4 million, compared to the year-ago quarter’s revenues of $41.6 million. While CDMO services revenues declined 67.9% year over year to $36.2 million, the CDMO lease revenues increased $71.2 million from the year-ago quarter, reaching $0.2 million.
The decline in CDMO services revenues was due to lower combined revenues of $82 million from AstraZeneca (AZN - Free Report) and Janssen, a Johnson &Johnson (JNJ - Free Report) subsidiary, which resulted in lower production-related work carried out at one of Emergent’s facilities, which reduced manufacturing activities. Emergent reversed $8.3 million of previously recognized revenues under the Janssen contract.
In July 2020, J&J and Emergent entered into an agreement to provide contract development and manufacturing (CDMO) services for J&J’s single-shot, adenovirus-based COVID-19 vaccine for five years. In June 2022, the companies announced their decision to terminate the deal, citing contract breaches.
The increase in CDMO lease revenues was driven by the reversal of revenues of $86 million in the third quarter of 2021 related to Emergent’s public-private COVID-19 development partnership with BARDA in November 2021. The increase was partially offset by a $15.1-million decline in lease revenues related to the contract with Janssen, a subsidiary of Johnson & Johnson.
We note that Emergent had received a setback last year when there was a manufacturing mishap at its Bayview facility where COVID-19 vaccine ingredients of J&J and AstraZeneca reportedly got mixed and led to several faulty batches of J&J’s vaccine. Emergent lost its contract for AstraZeneca’s vaccine following the mishap.
Emergent reported an adjusted EBITDA loss of $15.2 million for the third quarter, wider than the year-ago quarter’s loss of $3.3 million.
Emergent Biosolutions Inc. Price, Consensus and EPS Surprise
Emergent Biosolutions Inc. price-consensus-eps-surprise-chart | Emergent Biosolutions Inc. Quote
Update on 2022 Guidance
Emergent has issued fresh guidance for total revenues, adjusted EBITDA and CDMO services while providing updated ranges for its other business segments.
The company lowered its previous guidance for full-year 2022 revenues from the range of $1.15-$1.25 billion and now expects it to be between $1.05 billion and $1.10 billion.
Management revised anthrax sales guidance and currently expects sales of $260-$275 million from anthrax vaccines, down from the previous guidance of $280-$300. The company has raised the revenue guidance for Narcan nasal spray and smallpox vaccine. It now expects revenues from smallpox vaccine to be in the range of $63-$63 million compared with the previously guided range of $225-$250 million. Revenues from the Narcan nasal spray are expected to be between $350-$365 million, up from $300-$340 million expected previously. The projection for revenues from other products and Contracts and Grants was updated in the range of $167-$172 million from its previously expected range of $235-$240 million.
Emergent expects CDMO revenues to be in the range of $100-$110 million, revised from $1052 - $110 million.
The company now expects adjusted EBITDA in the range of $0-$30 million, down from $80-$120 million expected previously.
Emergent also anticipates lower adjusted net income(loss) within $(100)-$(70) million, compared to the previous expectation of $(15)-$10 million.
Zacks Rank
Currently, Emergent BioSolutions has a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.